Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lympho...

Lead sponsor: Kyowa Kirin Co., Ltd.•30 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

COMPLETEDPhase 1

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

NCT03985189 · Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

COMPLETEDPhase 1

GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma

NCT01933516 · Indolent B-cell Non-Hodgkin's Lymphoma

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 11, 2025Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhasePHASE2

Enrollment61

Start dateSep 2020

Last updatedSep 11, 2025

Condition

Indolent B-cell Non-Hodgkin's Lymphoma

Locations shown

Anjo Kosei Hospital

Anjo, Aichi-ken

Aichi Cancer Center Hospital

Nagoya, Aichi-ken

Japanese Red Cross Nagoya Daini Hospital

Nagoya, Aichi-ken

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 11, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions